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Lymphoid organs are meeting zones where lymphocytes come together and encounter
antigens present in the blood and lymph or as delivered by cells migrating from the drain-
ing tissue bed. The exquisite efficiency of this process relies heavily on highly specialized
anatomy to direct and position the various players. Gated entry and exit control access
to these theaters and reticular networks and associated chemokines guide cells into the
proper sections. Lymphoid tissues are remarkably plastic, being able to expand dramatically
and then involute upon resolution of the danger. All of the reticular scaffolds and vascular
and lymphatic components adapt accordingly. As such, the lymph node (LN) is a wonder-
ful example of a physiologic remodeling process and is potentially a guide to study such
elements in pathological settings such as fibrosis, chronic infection, and tumor metasta-
sis.The lymphotoxin/LIGHT axis delivers critical differentiation signals that direct and hone
differentiation of both reticular networks and the vasculature. Considerable progress has
been made recently in understanding the mesenchymal differentiation pathways leading to
these specialized networks and in the remodeling that occurs in reactive LNs. In this article,
we will review some new advances in the area in terms of developmental, differentiation,
and maintenance events mediated by this axis.
Keywords: lymphotoxin-beta receptor, reticular stroma, high endothelial venules, reactive lymph node, follicular
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INTRODUCTION
The functional specialization of the reticular scaffolds and the
vascular and lymphatic vessels in lymphoid organs is essential
for the exquisite sensitivity and efficiency of the immune system.
These various stromal elements have been increasingly well stud-
ied over the last decade with major advances occurring in the
description of their developmental lineages and differentiation
as well as their activation and adaptation in reactive lymphoid
organs. This field has been extensively reviewed (1–12). In gen-
eral, the stromal cells in the secondary lymphoid organs (SLO)
include reticular cells of which there are at least two different
kinds, the follicular dendritic cell (FDC) and the fibroblastic retic-
ular cell (FRC). Additional fibroblastoid cells are present in splenic
red pulp and in the medullary sinuses of the lymph nodes (LN)
(2). Cells of endothelial origin include blood endothelial cells of
which there are both conventional “flat” forms as well as high
endothelial venules (HEV) and the lymphatic endothelium that
lines the afferent and efferent lymphatics, the subcapsular sinus,
and the various lymphatic sinuses within the cortex, paracortex,
and medulla (13). These structures are relatively stable in the
resting state but undergo dynamic remodeling in the case of reac-
tive LN. Reactive LN normally involute and presumably restore
homeostasis once the activating trigger is resolved.
The lymphotoxin (LT) system, a member of the TNF family, is
a key regulator of lymphoid architecture. For almost two decades
now, the roles played by this pivotal system have been studied in the
context of the development and maintenance of lymphoid retic-
ular networks, HEVs, neo-angiogenesis, and lymphangiogenesis
as well as their impact on immunological function. This path-
way has been reviewed in detail (14–20). With a focus on recent
advances, we highlight here the role of the LT system in the con-
trol of the reticular and endothelial elements within organized
lymphoid structures.
THE LYMPHOTOXIN SYSTEM
The original LT protein, called LTα, is a member of the TNF fam-
ily of ligands and is secreted as a homotrimeric molecule. Like
TNF, LTα binds to the TNF receptors. An additional membrane
bound form of LTα is composed of a heterotrimeric complex with
a second protein called LTβ in a LTα1/β2 stoichiometry (LTα/β).
LTα/β binds uniquely to the lymphotoxin-beta receptor (LTβR)
(Figure 1). A second ligand, LIGHT (TNFSF14), binds to three dif-
ferent receptors; LTβR (TNFRSF3) with high affinity, another TNF
family receptor called HVEM (TNFRSF14) and a soluble receptor
named DcR3 (TNFRSF6B). LIGHT is found in both membrane
tethered and secreted forms. Dimerization of LTβR by either
LIGHT or LTα/β is sufficient to induce signal transduction (21,
22); however, it is likely that higher order oligomerization states of
the receptor lead to either more intense or qualitatively different
signaling (23). HVEM also interacts with several non-TNF family
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FIGURE 1 | Map of the interactions between LTβR, HVEM, andTNF
receptors with the LT/LIGHT family and the Ig-super family members
CD160 and BTLA. LIGHT is shown in its membrane bound form, but it is
also readily secreted like homotrimeric LTα.
members, i.e., BTLA and CD160 and these proteins have context-
specific regulatory effects on T and NK cell function (20, 24, 25).
Human but not murine LTα can bind to HVEM and LTα binds to
Troy (TNFRSF19) (26). However, these LTα interactions are low
affinity and their physiological significance is questionable (27).
The soluble human LTα trimer appears to have specific func-
tions. Most notably, LTα and LTβ knockout animals differ in that
LTβ−/− mice retain the mesenteric lymph node (mLN) while
LTα−/− mice lack all nodes (19). Likewise, the two LT knockout
animals differ in their ability to survive cerebral malaria (28). The
consequences of ectopic LTα gain-of-function in transgenic mice
differ depending on whether or not LTβ is expressed with periph-
eral lymph node addressin (PNAd) display requiring LTβ (29).
More recently, a specific role for LTα in the induction of gut IgA
responses was defined (30). Indeed, differences between LTα and
LTβ deficient mice have been attributed to additional and unique
roles for the LTα homotrimer. Whether such LTα-specific func-
tions are physiological can be questioned as the LTβ−/− mouse
represents potentially an LTα gain-of-function mouse. In a study
using transfected cells, LTβ expression dramatically rerouted LTα
expression into the membrane form to the detriment of secreted
LTα (31). Thus, the loss of LTβ could initiate an LTα-driven inflam-
matory response especially in mucosal environments when TNF
expression is minimal. In general, it is believed that the LTα/β
heteromeric ligand represents a direct cell-to-cell communication
system, whereas LTα3 is only secreted. In early studies, efficient
secretion or shedding of the LTα/β complex was not observed (31–
33); however, recently small amounts of shed LTα/β were detected
in the blood and synovial fluid from rheumatoid arthritis patients
using a highly sensitive assay (34).
The LTα/β-LTβR system has been implicated in many immuno-
logical events including maintenance of FDC networks, HEV,
specialized macrophages capable of antigen capture in the splenic
marginal zone and subcapsular sinus of the LN as well as dendritic
cell (DC) homeostasis and differentiation (19, 35). This system
also plays major roles in mucosal microenvironments with multi-
ple consequences for epithelial cell biology and host defense/repair
programs (36). LTβR signaling affects the state of specialized
epithelial cells within the medulla of the thymus (37). The role of
LT in epithelial cell interactions is beyond the scope of this review.
Both LTβR and TNF-receptors activate canonical NFκB signaling,
yet LTβR is distinguished by the efficient activation of the alter-
native NFκB pathway (19). Importantly, receptor internalization
is required to shift NFκB activation from the classical to the alter-
native pathway and the nature of the ligand, e.g., soluble LIGHT
vs. membrane bound forms of LIGHT or LTα/β may affect the
ability to drive receptor internalization (38). The alternative path-
way is typically linked to developmental and cell differentiation
programs in contrast to the predominantly inflammatory role of
the canonical pathway (39). The centerpiece of the alternate NFκB
pathway is NIK kinase activation and NIK is required for many if
not all of the developmental and differentiation events associated
with LTβR (19).
Lymphotoxin-beta receptor is readily observed on most non-
hematopoietic cells and on monocytic and DC lineages. Histori-
cally expression of the LT ligand was considered to be unique to
hematopoietic lineages, especially B cells, activated T cells includ-
ing Th1 and Th17 subsets, NK cells and innate lymphoid cells (40).
This picture has become fuzzier of late, since LTβ RNA is readily
observed in several other cell types such as in DC, hepatocytes, and
hepatic oval cells (13, 41, 42). As LTβRNA appears more abundant,
LTα expression has been viewed as the limiting element in control-
ling membrane LTα/β display. It is less clear how often LTβ RNA
reflects actual functional membrane LT, which requires expression
of both LT proteins. Bona fide surface LTβ protein was observed on
DC by histology and FACS; however, surface heteromeric LT α/β
protein capable of binding LTβR actually has not been described
outside of the hematopoietic system (43). As non-hematopoietic
lineage cells and myeloid lineages usually express LTβR, it is theo-
retically possible that functional ligand produced within such a cell
rapidly complexes with receptor, initiates signal transduction and
the complex is processed. In such a case, cell autonomous LTβR
signaling could be possible without actual transit to the surface
and, moreover, surface ligand detection would be difficult. Fur-
thermore, in cells with a high density of LTβR, there is evidence
for autonomous signaling in the absence of any ligand (44).
The LT genes lie within a cluster with TNF in the class III region
of the MHC and epigenetic control and chromatin organization
are key elements of the regulation of cytokine expression within
the cluster (45, 46). In general, understanding of the physiological
transcriptional control of the LT and LIGHT genes remains incom-
plete. The LTβ promoter uses Ets1, Sp1, NFκB, and Egr-1/Sp1
transcription factors to drive RNA expression and expression was
induced by TNF in a hepatocyte cell line (47). Furthermore, a
regulatory element in exon 4 of the LTβ gene appears to interact
with multiple sites within the TNF gene cluster (48). In general,
LTα is expressed by activated lymphocytes and NFAT, NFκB, Sp1,
and STAT elements are found within the promoter region. LTα
expression can be induced by interleukin-12 p40 homodimer in
myeloid lineages (49). Non-hematopoietic cells can also make LTα,
for example, vascular smooth muscle cells secrete LTα in response
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to extracellular nucleotide activation of the P2Y2 receptor (50).
Adding to this complexity, LTα RNA can be found in several
variants. Interestingly, an alternate core promoter residing within
the intron between exons 1 and 2 was predominantly utilized in
T cells stimulated with TGFβ1 or FGF-7 (51). Clearly, a better
understanding of the physiological regulation of the LT locus is
needed.
LYMPHOTOXIN AND THE DIFFERENTIATION STATES OF
RETICULAR FIBROBLASTS IN RESTING LYMPHOID TISSUES
The cells forming the lymphoid reticular scaffolds are of mes-
enchymal lineage and generally are grouped into two broad cate-
gories based on their locations within organized lymphoid organs
(Figure 2). FDC scaffold the B cell follicles and perform a mul-
titude of functions related to antigen-presentation, cell survival,
and handling of apoptotic cells (9–12). They possess a unique
recycling mechanism to protect captured antigen from degrada-
tion and retain it for long-term presentation (52). FDC express the
chemokine CXCL13 required for follicular compartmentalization
of B cells (10). The second major category of reticular networks
encompasses the T cell region of both LN and the spleen and is
formed by FRC (2, 5, 8). FRC have multiple functions including
the attraction of CCR7-expressing T cells and DC by expression of
CCL19 and CCL21, T cell survival signals, and formation of colla-
gen fibers. As such, they are fundamentally different from the FDC
networks. A third category called a marginal reticular cell (MRC)
has received recent attention. This cell sits under the subcapsular
sinus close to B cell follicles, combines elements of both FDC and
FRC and has been proposed to be a progenitor cell to the two
major lineages (5, 53). Within the FRCs, there is heterogeneity, for
example, VEGF-expressing FRC are enriched in vessel-rich areas
(54). Also, using a lineage-tracing system for past expression of
CD21, a population of mesenchymal cells in the T zone was iden-
tified that are similar to FRCs, yet express higher levels of TGFβ
and lower amounts of CCL19 and CCL21 relative to FRCs (55).
How these cells are related in lineage to the classical FRCs remains
to be determined.
To understand reticular cell differentiation pathways, it is
important to appreciate the embryological underpinnings of
LN development (16). Early LN anlagen are formed from
buds of endothelial and mesenchymal tissue. The mesenchy-
mal cells progress through an ICAM1/VCAM1+ intermedi-
ate phenotype and at this stage, upon LTβR activation by
hematopoietic lymphoid tissue inducer (LTi) cells, they acquire
an ICAM1/VCAM1/MAdCAM1+ stromal organizer phenotype
(56). This cell is often referred to as a lymphoid tissue organizer
(LTo). The LTo cells now express CCL19, CCL21, CXCL13, IL-7,
and RelB, and these markers will typify future specialized stro-
mal elements in the mature organ. The reliance on LTβR signaling
at the stromal organizer switching point is believed to account
for the impaired development of LN in mice deficient in com-
ponents of the LT pathway. Importantly, ontogeny has provided
an important guide in understanding lymphoid tissue changes as
embryological paradigms are largely recapitulated during inflam-
mation (57, 58). Studies on the role of the LT system have always
been plagued by the complexity of the direct knockout animals,
i.e., the lack of LN and the issues of dissociating embryological
FIGURE 2 | Examples of FDC and FRC networks in the human tonsil.
Top panel shows the podoplanin positive FRC network and lymphatic
vessels (both brown) and the surrounding HEV and non-HEV vessels (CD34,
blue). Bottom panel shows the FDC network (CD35, brown) in a secondary
follicle with a GC. Note light and dark (CD35 positive) regions are readily
discerned along with the residual primary follicle or mantle zone
surrounding the GC. L, lymphatic vessel; FRC, fibroblastic reticular cell,
HEV, high endothelial venule; M, mantle zone or primary follicle; GC,
germinal center or secondary follicle, DZ, dark zone; LZ, light zone.
programs including postnatal events from physiological main-
tenance/homeostasis. Historically, pharmacological inhibition of
LTβR signaling has been the most direct method to achieve dis-
section, however, cell-specific or inducible genetic manipulations
now provide powerful tools.
RETICULAR NETWORK PROGENITORS
The current paradigms for reticular cell specialization in the SLO
invoke an early progenitor cell that is somewhat similar to a
mesenchymal stem cell (MSC) (Figure 3) (6). Signals early in
development provided by retinoic acid or RET ligand depend-
ing on the context lead to an immature organizer cell (16). In
most contexts, LTβR signaling is required for progression to the
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FIGURE 3 | Putative differentiation pathways for the FDC and FRC networks showing major phenotypic changes. The MRC is speculated to be a
progenitor for FRC and FDC lineages based on phenotype, but this relationship has not been formally proven.
mature organizer or LTo that releases chemokines and displays
surface adhesion molecules to nucleate the emerging LN anlage.
Brendolan and colleagues recently were able to use lineage-tracing
methods to map this pathway using the transcription factors
Nkx2–5 and Islet1 (59). The Nkx2–5/Islet1 cells differentiated into
all three major reticular lineages, MRC, FDC, and FRC as well
as into classical mural cells or pericytes, but not the endothelial
lineages.
FDC NETWORKS
Lymphotoxin-beta receptor signaling is essential for the devel-
opment, differentiation, and maintenance of FDC networks in
the SLO, in mucosal compartments and in chronically inflamed
sites, i.e., so-called tertiary lymphoid tissues/organs (TLTs/TLOs)
(9–12). TNF signaling is also critical for the differentiation of
the FDC phenotype, but not FDC maintenance at least in a
secondary follicle. Surface LT on B cells is crucial for the devel-
opment and maintenance of the FDC networks in the spleen
as shown by the use of classical bone marrow chimeras and
more specifically with a conditional B cell selective knockout of
LTβ (60–63).
Historically, the term “dendritic cell” in this setting was an
unfortunate misnomer and contributed to the confusion sur-
rounding their true origin. Obscuring their origin even further,
FDC “precursors” could be transferred from bone marrow; how-
ever, this observation preceded the discovery of MSCs in the bone
marrow. In a breakthrough, the precursor cells to FDCs were
recently identified as perivascular cells resembling pericytes (64).
Pericytes are members of a subset of fibroblastoid cell types includ-
ing classical pericytes also called mural cells, vascular smooth mus-
cle cells, adventitial fibroblastoid cells, and stellate cells (hepatic,
pancreatic, pituitary, astrocytes, etc.). MSCs are progenitors of
both this immediate “pericyte” family as well as a much wider
group of cell types including adipocytes, chondrocytes,osteoblasts,
fibroblasts, myofibroblasts, synoviocytes, and podocytes. The exact
differences between MSC and perivascular cells or pericyte prog-
enitors remain murky (65, 66). There is some semantic confusion
as a pure classical definition of pericytes would include direct con-
tact with an endothelial cell without interruption by a basement
membrane. In practice, lacking unique cellular markers, there
appears to be a spectrum of related perivascular cells.
Aguzzi and colleagues used multiple approaches to understand
the origin of FDCs. They were able to lineage map PDGFRβ+
precursors into FDC and ablation of these same cells led to the
loss of FDC. Additionally, transfer of adipose-derived perivascu-
lar cells into the renal capsule resulted in the formation of a local
FDC network (64). B cells were the sources of LT and TNF for FDC
development, yet in the absence of B cells, LTi cells were implicated
as a key source of LT. It should be noted that these approaches were
not completely definitive, e.g., the markers PDGFRB and MFGE8
are not specific for pericytes and FDC, respectively. This limitation
in the study highlights how the pericyte field suffers from the lack
of absolutely unique markers (67). Nonetheless, PDGFRβ positive
cells in adipose tissue are generally accepted to be a pericyte/MSC
and these cells were able to give rise to FDCs. Therefore, the differ-
entiation of mesenchymal progenitor cells into a reticular cell that
is highly honed to retain antigen within the follicular microenvi-
ronment, requires either LT or TNF signaling provided by local
lymphoid cells. This system provides an excellent example of the
ability of the lymphoid cells to locally shape mesenchymal lineages.
Established FDC networks exist in both a primary form, i.e., in
a follicle lacking a germinal center (GC) reaction or in GC con-
taining secondary follicles wherein the network is further differ-
entiated (10, 68). Maintenance of established networks absolutely
requires LTβR signaling as shown by pharmacological inhibition of
the pathway (69–73). Mice genetically deficient in elements of the
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LT system have been instrumental in defining the roles of splenic
FDC. For example, spleens from LT-deficient mice displayed vastly
reduced CXCL13 expression and pharmacological inhibition gave
roughly similar results (74). Using various LT pathway deficient
mice or bone marrow chimeric mice, lack of FDC resulted in pro-
found impairment in both class switch recombination and affinity
maturation. These results were probably complicated by additional
defects in the splenic marginal zone, trafficking of cells to the cor-
rect compartments, and DC biology, etc. (14, 75). For example, the
impressive loss of immune complex trapping on splenic FDCs in
monkeys following LTβR inhibition was potentially a combination
of both degradation of antigen trapping machinery in the primate
marginal zone as well as FDC collapse (71).
The impact of FDC disruption has been studied by many
approaches, but a selective depletion system described recently
by Cyster and colleagues provided a relatively clean analysis (76).
Loss of FDC networks collapsed follicular organization, reduced
CXCL13 chemokine production and led to abortive GC reac-
tions probably due to lack of long-term antigen retention (76). In
monkeys, splenic FDC networks were substantially collapsed after
only 1 month of pharmacological inhibition of LTβR signaling
(71). Curiously, GC reactions in the mLN may be less depen-
dent on proper FDC networks than in the spleen or peripheral
LN (pLN) (76). mLN are clearly different from pLN in terms of
their developmental requirements (76–79). In general, the role of
LTβR signaling in FDC maintenance during a GC reaction remains
poorly described.
FRC NETWORKS
Fibroblastic reticular cell are reticular cells that scaffold the T cell
rich regions of organized lymphoid structures (1, 2, 4, 7, 8). The
chemokines CCL19 and CCL21 are produced by FRC and orches-
trate the movement and attachment of lymphocytes along this
backbone with DCs being more tightly attached and T cells loosely
marching along the network to spatially facilitate T-DC encoun-
ters. Clean experiments to dissect immune function in the presence
and absence of FRC are lacking and indeed some have questioned
how much the FRC actually facilitates encounters (80). FRC also
provide the IL-7 for T cell survival and the control of homeostatic
compartment size in a manner reminiscent of BAFF and B cell
survival (81). FRC have the capacity to directly present antigen
to promote peripheral tolerance and they can respond with nitric
oxide production during acute inflammation thereby dampening
T cell responses (82–84). The scaffold itself is composed of col-
lagen fibers that are made and wrapped by the FRC, forming a
functional unit called a “conduit” (85). These conduits are found
in all lymphoid tissues, e.g., spleen, thymus, LN, and TLT and
appear intrinsic to an organized microenvironment. The conduits
allow for very fast transport of low molecular weight proteins,
i.e., up to roughly 70 kDa from the lymph or blood to the LN
parenchyma. DC residing on the FRC can sample the conduit
contents, raising the potential for direct detection of small anti-
gens. Additionally, it is reasonable to propose that conduits allow
the LN to sense chemokine/cytokine signals emanating from an
inflamed tissue bed.
Recently, three studies have contributed greatly to understand-
ing FRC differentiation. First, the Turley group in conjunction
with the Immunological Genome project purified and analyzed
the transcriptomes of FRC, blood endothelial, and lymphatic
endothelial cells along with a fourth so-called double-negative cell
(DNC) population that was negative for the endothelial marker
CD31 and the FRC marker podoplanin (86). The DNC popula-
tion was pericyte-like and most closely resembled FRC. This work
provided a unique molecular fingerprint of these stromal popula-
tions and suggested a lineage relationship between pericytes and
FRC. Caamano and colleagues showed that embryonic progeni-
tor cells resembling preadipocytes can differentiate into lymphoid
stromal cells (87). LTβR signaling, via the alternate NFκB path-
way, was required to stop a progenitor cell from embarking on an
adipocyte program and to direct a shift toward a lymphoid stromal
cell differentiation pathway. This capacity was demonstrated using
both embryonic and adult progenitors derived from adipose tis-
sue. Moreover, they hypothesized that adipose tissue is a source
of lymphoid stromal cells. Consistent with these observations,
LIGHT-LTβR interactions can inhibit the program of adipocyte
differentiation (88, 89). Third, Ludewig and coworkers exploited
a unique CCL19-Cre mouse with expression limited to the FRC
(90). Using this tool, LTβR could be selectively deleted from FRC-
like cells. Surprisingly, these mice developed LN and FRC/conduits
normally; however, the LTβR-deficient FRC displayed reduced
CCL19, CCL21 chemokine, and podoplanin expression. It is likely
that insufficient CCL19 driven Cre is expressed at the early prog-
enitor phase to remove LTβR prior to LTo generation and hence LN
development proceeds normally. The mice bearing LTβR-deficient
FRC poorly managed a murine herpes virus infection suggesting
defective FRC diminished the immune response. These studies
indicate that some aspects of FRC are under LT control, both devel-
opmentally and upon ectopic relocation, i.e., a setting similar to
the induction of TLT.
Therefore, it appears that, like FDC, de novo development of
FRC requires LTβR signaling. This result was best illustrated in
the earlier observations on the formation of FRC networks in the
spleen and TLT (74, 91). Despite these elegant studies, the basic
question is less clear as to whether established FRC networks in
either resting or reactive LN are under continuous LTβR control
as observed with FDC. In prior analyses by the Cyster group, there
was a clear developmental dependence on LT positive B cells for
the splenic T zone FRC and their expression of CCL21 (74, 92).
The development of splenic FRC, like FDC, continues from birth
out for several weeks and indeed neonatal inhibition of LTβR sig-
naling reduced CCL21 levels (a surrogate for FRC maturation)
(92, 93). However, neither pharmacological inhibition of LTβR in
adult mice nor transfer of LT-deficient lymphocytes appreciably
reduced CCL21 levels in either spleen or mLN (74, 92). As in the
spleen, FRC in LN continue to develop for 2–6 weeks post gestation
based on CCL19 expression (90). The loss of LTβR on FRC using
the CCL19-Cre system caused major disruptions in the nature of
the FRC network (90). Likewise, combined TNF and LTβR signal-
ing was synergistic leading to generation of collagen containing
conduit-like fibrils in cultures of LN-derived stromal cells (94).
One interpretation of this result is that canonical NFκB signaling
by TNF is required to resupply the components to drive long-term
alternate NFκB signaling by LTβR. In the light of these vari-
ous observations, it is perhaps perplexing that pharmacological
www.frontiersin.org February 2014 | Volume 5 | Article 47 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lu and Browning Lymphotoxin and lymphoid architecture
LTβR inhibition in adult mice did not affect CCL21 levels. How-
ever, these observations are consistent with a developmental role
for LTβR signaling in FRC development, but not in the main-
tenance of established networks. Further histological analysis of
non-matrix markers such as podoplanin, PDGFRβ, etc., expres-
sion in FRC networks following LTβR-Ig treatment need more
careful examination. Therefore, in contrast to FRC development
and FDC networks, the existing data indicate that the maintenance
of established FRC networks is not under LT control.
THE ROLE OF THE LYMPHOTOXIN SYSTEM IN REGULATION
OF THE RESTING LYMPHOID ENDOTHELIUM
HIGH ENDOTHELIAL VENULES
A prominent feature of LN is the presence of specialized post-
capillary venules called HEVs that allow for the transit of lym-
phocytes from the blood into the LN parenchyma (13). The
selective display of various adhesion molecules, coupled with spe-
cific chemokine triggers for integrin activation differentially gate
access to the unique microenvironments of the skin, mucosa,
and various LN. The robust transit of lymphocytes through the
endothelium presses the endothelial cells into plump shapes giv-
ing the venule its characteristic “high” status (95). Development
and maintenance of the HEV specifically requires LTβR signaling
via the alternative NFκB pathway with a dialog occurring between
LT positive DC and LTβR positive endothelial cells to promote the
“HEV program” (96–98). The role of LTβR in HEV maintenance
was conclusively demonstrated by pharmacological intervention
of LTβR signaling in adult mice (99, 100). Developmentally, the
requirement for LTβR signaling was less obvious since LN devel-
opment itself is arrested in knockout mice, although addressin
expression was reduced both in the mLN in LTβ deficient mice and
in the occasional LN that develop following gestational inhibition
of LTβR signaling (101, 102). Recently, deletion of LTβR expres-
sion selectively in endothelial lineages curtailed development of a
normal repertoire of LN’s, yet HEV development was blocked in
remaining rudimentary LN (103). This study proved that the HEV
program was directly under LTβR control and not a consequence
of more indirect events related to a disrupted lymphoid architec-
ture. Although some HEV are also associated with the pericyte-like
DNCs (86), FRC appear to extend directly to the HEV, and wrap
the abluminal face (104). It is conceivable that the FRC/HEV acts
as a unit comparable to the astrocyte/pericyte/endothelial cell neu-
rovascular unit or the relationship between stellate cells, pericytes.
and endothelial cells in the liver sinusoids.
The PNAd molecule on HEV is a complex sulfated glycan
assembled on specific scaffold proteins in both N- and O-linked
forms. PNAd binds to L-selectin on the lymphocyte triggering the
initial rolling. The basic LTβR-controlled “HEV program” encom-
passes the direct induction of scaffold gene expression in LN such
as MAdCAM1, GLyCAM1, and CD34, as well as the biosynthetic
machinery needed to assemble on the scaffold proteins the unique
sulfated glycans that bind to L-selectin (13). MAdCAM1 is an
addressin for the integrin α4β7, as well as itself being a scaf-
fold for PNAd attachment. Vascular MAdCAM1 expression in the
mLN is LTβR-dependent, although inflammatory signals such as
TNF or secreted LTα can also induce MAdCAM1 expression (13).
MAdCAM1 expression on the sinus floor of the splenic marginal
zone and on FDCs is also LTβR-dependent as is mostly likely the
expression on MRCs and the LN subcapsular sinus (105). Vascular
MAdCAM1 is elevated in colitis in an LTβR-dependent manner;
however, it is unresolved whether this component is indirect and
secondary to effects on the disease processes (14).
HEV can readily accumulate radiolabeled sulfate and contain
elevated levels of the machinery involved in sulfate uptake and
transport (106, 107). In addition to specific sulfated glycan that
comprise PNAd, sulfation is also involved in chemokine retention.
Heparin sulfate is crucial for endothelial chemokine binding and
lymphocyte trafficking as well as DC recruitment to the lymphat-
ics (108). Whether there is any dependence on LTβR signaling for
endothelial sulfate capture or sulfated matrix components has not
been explored.
While considerable progress has been made uncovering the role
of the LT pathway in lymphoid vascular biology, there remain
murky aspects of HEV development and specialization within
unique environments, e.g., mucosal, peripheral, TLT, tumor, etc.
For example, the homeodomain transcription factor Nkx2.3 con-
trols vascular compartmentalization in the spleen yet its deletion
led to the formation of splenic HEV-like vasculature complete
with expression of PNAd and CCL21 (109). HEV formation
remained LTβR-dependent in line with the appearance of splenic
PNAd positive structures in a mouse with a constitutive gain in
alternative NFκB signaling (110). Nkx2.3 deficiency also led to
altered splenic FRC structures and the presence of LYVE1 positive
lymphatic-like structures thus pivoting the spleen toward an “LN
architecture” (111).
LYMPHATICS
The afferent lymphatics transport cells and soluble substances
from the draining tissue to the subcapsular sinus. From the sub-
capsular sinus, DC find their way into the T zone parenchyma
while T cells either flush through or they can enter the LN
parenchyma via peripheral medullary sinuses (112). Recirculat-
ing lymphocytes leave the LN parenchyma by entering cortical
sinuses that feed into medullary sinuses and efferent lymphatics
(113). The lymphatic endothelial cells are an important source
of sphingosine-1-phosphate that elicits lymphocytes to leave the
parenchyma and enter the sinuses (114). Whether LTβR signaling
is crucial for lymphatic function is less clear, although defects in
lymphatic function were observed in LT-deficient mice (115).
LYMPHOTOXIN PATHWAY AND ADAPTATION IN THE
REACTIVE STATE
During immune responses, the reticular networks and the
endothelium undergo growth and remodeling with an overall
increase in LN cellularity. Such enlarged LN are termed “reac-
tive” and normally the LN involute and return to the resting state
once the triggering stimulus is resolved. Experimentally, reac-
tive LN are induced by immunization with an adjuvant such as
alum, complete Freund’s adjuvant (CFA) or Montanide, or by
infection with a pathogen. Total LN cellularity in both the rest-
ing and hypertrophic reactive state is LTβR-dependent (99, 116,
117). Whether the stroma or vasculature bears an imprint of
prior reactivity is unknown, although gross lymphangiogenesis
following inflammation is certainly reversible (118).
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RETICULAR NETWORK
Within the T zone, the reticular network expands with the enlarg-
ing T zone and the stromal cells undergoing proliferative expan-
sion (119–121). The concentration of reticular fibrils under the
follicles where T cells frequently interact with DC is known as
the cortical ridge and this ridge becomes more prominent after
immunization with ovalbumin (OVA) in alum (119). Following
immunization with OVA in CFA, the stromal cells undergo an ini-
tial proliferative burst between days 0 and 2 that is dependent on
CD11c+ DC cells and independent of lymphocytes. This burst is
followed by continued proliferation and expansion in cell num-
bers that is detectable by day 5. The expansion was abrogated
in the absence of lymphocytes and B cells contributed to the
full expansion, while T cells contributed to the continued high
proliferation rate (120). Recently, Luther and colleagues carefully
analyzed changes in the FRC network following immunization
with OVA in the adjuvant Montanide in mice containing trans-
ferred OVA specific T cells (121). Similar to changes induced
with OVA/CFA, OVA/Montanide-induced a rapid CD11c+ cell-
dependent stromal proliferation, and modest stromal expansion
could be detected within 40 h. Stromal cells continued to prolif-
erate and expand, and the expansion by day 5.5–6 was abrogated
in RAG2−/− mice. Significantly, this study revealed that LTβR-Ig
treatment did not affect the modest expansion at day 3, but did
reduce FRC expansion at day 5.5–6 suggesting a role for LTα/β
expressed by lymphocytes. A number of genes were previously
shown to be altered in activated FRC and in this recent study, these
cells displayed elevated levels of podoplanin and smooth mus-
cle actin (86, 121). While maintenance of the resting FRC is not
obviously under LTβR control, it is clear that events occurring in
reactive FRC are LT/LIGHT-dependent and this dependence may
underlie partially the profound effects of LTβR-Ig treatment on
reactive LN. Again, the reticular changes occurring during inflam-
mation appear to recapitulate programs that are utilized during
development.
As hinted above, reticular networks may differ in their response
to various immunological challenges including acute vs. chronic
settings. For example, in contrast to Alum, CFA as an adjuvant
leads to disruption of normal ER-TR7 patterning (ER-TR7 is a
marker of collagen fibrils that is usually a surrogate for FRC pres-
ence), with loss of distinct B and T zones (119). A more detailed
analysis of the time course is needed to determine whether the
distinctions between Alum and CFA may in part reflect differ-
ences in kinetics. During a viral response, such as with LCMV
infection, CCL21 and CXCL13 chemokine expression is downreg-
ulated during the first 8 days in the spleen and this response was
partly dependent on interferon-γ but was minimally impacted by
LTβR-Ig (119, 122, 123). The same process occurs in draining LN
(123). Although, the LCMV clone-13 strain can infect the FRCs,
this phenomenon of chemokine downregulation also occurred
with OVA/LPS suggesting that this is a general phenomenon in
inflamed lymphoid tissues (123). The loss of chemokine expres-
sion with viral infection may be in part attributable to loss of
stromal cells (122). After this initial viral-induced stromal disrup-
tion, stromal cells recover and lymphoid organization is gradually
restored. It is this process of recovery that is accelerated by LTi cells
and is at least partially dependent on LTβR (122).
During LN hypertrophy, some of the most notable changes
occur in the medulla (121, 124). This compartment normally
appears condensed at homeostasis, but upon immune stimula-
tion, the region swells and fills with lymphocytes. By day 6 after
NP-OVA/CFA immunization, the parenchyma is enlarged relative
to the area covered by the lymphatic marker LYVE1, and areas of
collagen IV reticulum-rich and reticulum-poor areas can be iden-
tified. B cells are preferentially localized to the reticulum-poor
area and newly generated plasma cells localize to the reticulum-
rich areas. The significance of this compartmentalization remains
to be elucidated. Medullary remodeling was reduced by LTβR-Ig
treatment in a manner that appeared independent of its effects on
FDC and HEV (124).
VASCULATURE
Following immunization, the vasculature also undergoes prolifer-
ative expansion that is accompanied by major phenotypic changes
in the HEV. HEV, non-HEV blood endothelial cells, and lym-
phatic endothelial cells all proliferate and expand coordinately
with remodeling of the feeding arteriole to deliver more blood
flow (100, 120, 125–128). Similar to stromal cell growth, endothe-
lial cells in LNs stimulated with OVA/CFA undergo initial CD11c+
cell-dependent proliferation followed by lymphocyte-dependent
expansion (120, 125). HEVs can be seen to grow in length, width,
and branching as imaged using optical projection tomography
(116, 129). The HEV expansion triggered by LCMV infection is
sensitive to LTβR-Ig and partially dependent upon B cell-derived
LT. As B cells are not required for HEV maintenance at homeosta-
sis (99, 100), this role of B cell-derived LTβ appears to be specific
to the inflamed LN. With inflammation, there is the phenomenon
of venularization whereby adjacent endothelium adopts a post-
capillary venule phenotype (130). In inflamed LN, this change
seems to occur as HEV (i.e., PNAd+) endothelial cells expand to
a greater degree than PNAd-blood endothelial cells (120). One
unresolved question is whether the reduction of HEV expansion
in the absence of LTβR signaling reflects inhibition of HEV dif-
ferentiation or inhibition of HEV proliferation? Anderson and
colleagues observed that endothelial cell proliferation occurred
frequently at transitions between high and flat endothelium, con-
sistent with simultaneous proliferation and differentiation (131).
Another area that is still poorly understood is whether the LTβR-
dependent HEV expansion reflects LTβR function in reticular cells,
DC, or the endothelial cells.
In the reactive LN,numbers of both blood vessels and lymphatic
sinuses increase and this expansion is accompanied by lymphatic
endothelial cell proliferation (100, 120, 126). The increase in the
number of lymphatic structures was partly sensitive to LTβR-Ig
(100), but it is unknown whether LTβR-Ig blocked proliferation
or impacted other facets of lymphatic growth. Somewhat sur-
prisingly, LTβ−/− mice showed greater lymphangiogenesis and
angiogenesis in inflamed lung and skin and hence, the general
role of LTβR in LN vascular growth remains ill-defined (115).
In contrast, LTα−/− mice showed reduced lymphatic function
and reduced lymphangiogenesis with skin inflammation, and
transgenic LTα expression drove lymphangiogenesis, suggesting
a pro-lymphangiogenic role for LTα3 as well as a role for LTαβ in
“sequestering” LTα subunits. In agreement with a role for LTα3,
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FIGURE 4 | Illustration of some of the changes that occur in the
FRC-vascular units during the resting to reactive transition in a lymph
node.
TNF inhibition or TNFR1 deficiency were shown to partially
reduce lymphangiogenesis in lung (132).
In addition to proliferative expansion, the HEVs also undergo
phenotypic alterations. The phenotypic changes seen in reac-
tive HEV are illustrated in Figure 4. At day 1 after injection of
bone marrow derived DCs or OVA/CFA immunization, VCAM1
is upregulated and there is a greater trafficking of lymphocytes
inwards via HEVs (104). This early change corresponds to dis-
ruption of the tight sheath of FRCs around vessels and the HEV
activation is similar to the early ICAM1 upregulation seen after
fever-range thermal stress (104, 133). By day 4 after oxazalone
stimulation, HEV endothelial cells show reduced expression of
proteins associated with the mature HEV program, i.e., LTβR,
the scaffold protein GlyCAM1, and the sulfo-transferase HEC-
GlcNAc6ST (100, 134). The downregulation of these HEV pro-
gram proteins was accompanied by upregulation of MADCAM1
perhaps reflecting an immature HEV, since MADCAM1 is nor-
mally only expressed in peripheral nodes during development and
in mucosal lymphoid tissues (100, 135). In the same time frame,
LTβR expression decreases and PNAd and LYVE1 were colocal-
ized despite LYVE1 being a typical lymphatic marker (100). It was
unclear from this study whether this colocalization resulted from
lymphatics that expressed PNAd or HEVs that expressed LYVE1.
However, vessels with the morphology of HEVs in non-Hodgkins
lymphoma patients expressed LYVE1 and blood vessels during
development can express LYVE1, suggesting that the colocaliza-
tion of PNAd with LYVE1 represents HEVs that have upregulated
LYVE1 (136, 137). This PNAd/LYVE1 colocalization at day 4 was
blocked by LTβR-Ig treatment at day 0 (100). By day 7, the mature
HEV markers began to rebound while MADCAM1 and LYVE1
regressed, and this rebound phase was dependent on B cells and
also sensitive to LTβR-Ig.
The reprograming of the HEV differentiation state as a LN
enters the reactive state was noted to be similar to changes occur-
ring after surgical interruption of afferent lymphatic flow (99,
100, 138). Consistent with this notion, Ruddle and colleagues
showed a transient reduction in LN accumulation of subcuta-
neously injected Evans blue and skin-derived DC in the first
4 days after the onset of inflammation, which was followed by
increased lymphatic flow (100). In contrast, Randolph and col-
leagues showed increased LN accumulation of skin-derived DC in
the same time frame (126). These studies both applied FITC epi-
cutaneously in pre-immunized mice and then tracked FITC+DC,
and it remains unresolved whether the differing results reflected
different preimmunization strategies (oxazalone application vs.
KLH/CFA injection) or different kinetics of these strategies. In
human subjects, Braathen and colleagues measured lymphatic
flow via cannulation of a dermal lymphatic, and found that appli-
cation of a skin irritant resulted in a transient reduction in dermal
lymphatic drainage before the drainage increased to above baseline
(139). Whether the transient decrease was related to the trauma
of skin cannulation 2 days prior is a caveat in interpreting the
findings, although the trauma itself could be taken as a form of
immune stimulation. However, with regard to the idea of HEV
reprograming, the basic biological event that underlies this phe-
nomenon remains a question, i.e., is it the disrupted flow, the
inflammation or a dilution of LTβR signaling due to loss of ligand
and/or receptor? Do the HEV in the inflamed LN need trans-
port of soluble factors or cells via the lymphatics to prevent the
reprograming?
PUTTING IT TOGETHER IN THE REACTIVE NODE:
COORDINATE REGULATION OF VASCULATURE AND
STROMAL ALTERATIONS AND THE ROLE FOR LTβR
SIGNALING
Figure 5 presents a generalized view of some of the changes occur-
ring in the LN as it cycles between resting and reactivity. In the
first 2 days following immunization with OVA/CFA or bone mar-
row derived DCs, there is a lymphocyte-independent initiation
phase marked by endothelial and reticular cell proliferation with
parallel VCAM1 upregulation on HEV. From days 3–5, there is
an expansion phase whereby endothelial cells and stromal cells
continue to show high levels of proliferation and now notice-
ably expand in number. This expansion in most cases is at least
partly dependent upon B cells and T cells contribute partially to
the continued high level of endothelial and stromal cell prolifer-
ation during this phase (100, 120, 121, 124–126). The expansion
phase correlates well with the morphologic HEV expansion that
is dependent on B cell-derived LTβ and the LTβR-Ig sensitive
OVA/Montanide-induced FRC expansion (100, 116, 121). In this
context, the upregulation of MADCAM1 and downmodulation
of GlyCAM1 and HEV-GlcNA6ST observed by day 4 and could
potentially represent a reinstatement of the HEV programing that
typically occurs during early LN anlage development either in early
activated HEV cells or in newly expanded cells (100). Assuming
that the colocalization of LYVE1 with PNAd by day 4 represents
upregulation on HEV cells, consideration of the potential sig-
nificance of LYVE1 alterations may provide some clues. LYVE1
on developing skin collecting lymphatic vessels is downregulated
with the recruitment of smooth muscle cells (140), correlating
vascular destabilization/immaturity with LYVE1 expression. Dur-
ing the initiation phase, the tight, presumably stabilizing sheath
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FIGURE 5 | Drawing shows the cycle that lymph nodes transit from
resting to reactivity with some of the changes occurring at each stage.
The actual timing of each stage will depend on the nature of the reactive
trigger, e.g., immune complex, innate stimuli, virus, etc., and its
subsequent clearance.
of FRCs around the vessels is disrupted and vascular permeabil-
ity is increased (104, 131). It is conceivable that upregulation of
LYVE1 on HEV cells, like VCAM1 upregulation is an early activa-
tion marker that reflects a state of HEV destabilization. Taking
the LYVE1 upregulation as a marker of early HEV activation,
then, both early HEV activation as well as subsequent expansion
appears to be dependent on LTβR, and we would predict that the
MADCAM1, GlyCAM1, and HEC-GlcNA6ST alterations are also
LTβR-dependent.
The disrupted organization of FRCs around vessels during the
initiation phase probably reflects a more general reticular network
disorganization that was seen with OVA/CFA or, with a mild delay,
with viral infection. The viral-induced stromal dysfunction was
minimally sensitive to LTβR-Ig (123) suggesting that the reticular
network disruption may be relatively LTβR-independent. Thus,
early vascular and stromal changes in the reactive node may be
differentially regulated by LTβR signals. This is in contrast to the
later, LTβR-dependent reticular remodeling.
After the expansion phase, the vasculature undergoes a phase
wherein quiescence and stabilization are re-established. By day 7,
mature HEV markers rebound, robust endothelial cell prolifera-
tion slows and FRCs re-organize more tightly around the vessels
(100, 104). Thus, restoration of mature HEV markers parallels
the re-establishment of vascular quiescence/stabilization and stro-
mal integrity. The LTβR-dependent stromal recovery after viral
infection that was studied in the spleen may correspond to this
phase in the LN, and, if so, would further support the idea of
a global vascular-stromal re-stabilization. Whether, LTβR signals
are needed for all the vascular changes and how the medullary
remodeling is connected is unknown.
Following the vascular quiescence and stabilization phase, there
is additional growth, at least in the lymphatic vasculature as well
as considerable medullary remodeling (100, 124, 141). Lymphatic
expansion is B cell dependent up to at least day 7, but by day 14,
lymphangiogenesis is occurring in the absence of B cells (100).
This late lymphangiogenesis coincides with expansion of corti-
cal and medullary lymphatic sinus relative to that of subcapsular
sinuses, which expanded at an earlier time point (141). This obser-
vation suggests that some cortical and medullary expansion is
B cell-independent. LTβR signaling appears to be important for
medullary remodeling, but the actual specifics of which events
are being regulated needs further investigation. Any role for the
LT pathway in the restoration of homeostasis or the “involution
phase” is also unexplored.
In conclusion, LTβR signals in the reactive LN are needed for
multiple phases of vascular and stromal alterations, yet major ele-
ments of this picture remain out-of-focus. How exactly does LTβR
control the initial growth and phenotypic alterations? Do these
requirements reflect homeostatic functions of LTβR or are these
new functions in the context of an inflamed LN? Fu and cowork-
ers recently showed that LIGHT-LTβR signaling was important
for the growth of reactive nodes but not for homeostatic LN cel-
lularity suggesting that additional LTβR ligands and functions are
engaged in the reactive setting (117). Lastly, does the rebound of
mature HEV markers and the stromal re-organization indicate an
increased level of LTβR signaling during the phase of re-established
quiescence and stabilization?
LTβR AND TISSUE REMODELING IN DISEASE
CHRONIC REACTIVITY IN LYMPH NODES
Chronic LN reactivity can change lymphoid architecture and this
phenomenon has been well described especially in the context of
viral infection (2, 3, 142). In primates, both HIV and SIV infection
led to altered FRC function and a lack of T cell survival support.
Interestingly, the chronic reactivity in HIV infected LN culminates
in fibrosis perhaps mimicking aspects of other fibrotic diseases
(143). This observation is consistent with increased smooth mus-
cle actin expression in the FRC in reactive murine LN (121).
Reactive LNs, hyperplasia, lymphadenopathy, and probably imbal-
anced reticular networks often characterize autoimmune disease
(144). For example, abnormal FDC networks were noted in some
SLE patients, albeit there is considerable heterogeneity in this pop-
ulation (145, 146). Additionally in rodent models of lupus, FDC
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networks are altered in the MRL.lpr mouse (147). Aging is also
associated with some degradation of lymphoid architecture (148).
In most of these cases, the relationship to potentially impover-
ished LTβR signaling is unknown. Given the need for organized
lymphoid architecture in a well-functioning immune system, this
remains an important area for further investigation.
TERTIARY LYMPHOID TISSUES
Chronic inflammation drives the formation of semi-organized
lymphoid structures in basically all organ settings including lungs,
heart, stomach, intestine, kidney, CNS, glands, skin, joints, and vas-
culature (149–153). These TLT are also present physiologically in
the gut where they develop upon colonization with the micro-
biome (154). A wide spectrum of structures can be observed
ranging from relatively poorly organized perivascular aggregates
to more complete LN-like structures that display HEV devel-
opment, T/B cell segregation, GC formation, and the presence
of specialized FDC and FRC reticular networks (152, 153). For
example mature TLT are found in salivary glands in female NOD
mice, yet a B cell dominated structure lacking FDC networks is
observed in the young male NOD lacrimal glands (155, 156). TLT
can accompany Th1 and Th17 driven responses and even assem-
ble next to classical Mycobacterium-driven granulomas (157–159).
Notably, TLT are induced by ectopic expression of LTα or com-
bined LTα and LTβ in multiple organ systems and these studies
have provided considerable insight into the biology of these struc-
tures (42, 149, 160). There appear to be multiple routes to TLT
formation including those induced by RORγt positive cells such
as type III innate lymphoid cells (ILC-3) in the gut as well as
RORγt independent events (161). Simple ectopic overexpression
of several chemokines is sufficient to culminate in TLT forma-
tion (152). In general, regardless of the inducing trigger, signaling
by LTβR is essential for the formation of mature TLT in most
settings with the exceptions being relatively small, more poorly
organized structures (14, 91, 152, 162). FDC and especially HEV
formation in TLT is clearly reduced following pharmacological
inhibition of the LT pathway (155, 156, 162). In a mouse pancreas
model, large TLT were dissociated by LT pathway inhibition, yet in
the small remaining residual T cell rich zones, the FRC networks
appeared fully developed with conduits (91). This result is con-
sistent with the viewpoint that FRC maintenance is LT pathway
independent.
In a major knowledge gap, the contribution of TLT to pathol-
ogy is defined predominately by correlation and association. The
presence of TLT in man is associated with more severe disease,
e.g., in juvenile dermatomyositis, Sjogren’s syndrome, and multi-
ple sclerosis (163–165). In rodents, TLT can enhance viral defense
in lung infections, naïve T cell recruitment, and epitope spreading
in diabetes and exacerbate heart allograft rejection (152, 166–168).
Furthermore, HEV can be found in the absence of mature TLT
and, indeed, simply the emergence of cardiac HEV is a strongly
prognostic for pending heart graft rejection (169).
TUMORS
The role of the LT pathway in tumor biology has become an
active area. LTβR signaling can promote tumor metastasis by
maintaining a level of pro-inflammatory signaling (170–173). In
preexisting tumors, the formation of HEV within tumors appears
to be beneficial presumably by allowing for entry of a wider range
of lymphocyte subsets and enhanced tumor immunity (174). HEV
are found in melanoma tumors often in close proximity to LTβ-
expressing DC suggesting that processes are in play analogous to
those maintaining HEV in LN (43).
FUTURE DIRECTIONS
A clear picture of the integration of the vascular and reticu-
lar networks in the primary, secondary, and tertiary immune
organs in resting, reactive, and pathological states is essential to
an understanding of how the immune system maintains optimal
sensitivity and selectivity. It is also reasonable to assume that many
pathological events revolve not only around altered adaptive and
innate immunology, but also on altered stromal elements, e.g., HIV
infection. The LT system is clearly interwoven in some of these
processes, yet many of the studies have blurred the distinction
between developmental and maintenance controls. More work is
required especially at the clinical level to understand the contri-
butions of the LT system in human disease and it is fortuitous
that various clinical interventions are targeting LT (anti-LTα anti-
body), LIGHT (anti-LIGHT antibody), and both LT and LIGHT
(LTβR-Ig).
Certainly studies of stromal cell states in lymphoid tissues serve
to expand the basic knowledge of these differentiation programs
and the reactive state is a model of controlled inflammation in a
lymphocyte-rich environment. Importantly, the LN can return to
the resting state – a perfect example of physiological tissue remod-
eling. Studying the lymphoid setting may help one comprehend
the interplay between chronic inflammation, vascular damage, and
stromal cell activation present in many diseases. Given the success
of recent immunomodulatory strategies in oncology, manipula-
tion of the HEV entry portals for lymphocytes as well as modifica-
tion of lymphocyte–tumor stroma interactions could be very pro-
ductive approaches (174, 175). There is considerable interest in the
control of the differentiation pathways leading from mesenchymal
lineages into the myofibroblastoid cells driving pathological tissue
remodeling and fibrosis (176). For example, vascular disruption
and dysfunctional pericyte-endothelial cell interaction appears to
be occurring in many pathological conditions including sclero-
derma, interstitial lung disease, lupus, multiple sclerosis, some
neurodegenerative diseases and diabetic retinopathy, to name a
few (67). It is possible that important lessons can be gleaned from
the analysis of these cells in lymphoid microenvironments.
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